title: [Factors influencing prevalence and clinical course of cytomegalovirus (CMV) infection in kidney transplant patients].
abstract: In the paper the authors tried to identify factors influencing prevalence and clinical course of cytomegalovirus (CMV) infection in kidney transplant patients. The study was performed in the group of 100 patients after cadaveric kidney transplant followed up in the Chair and Department of Nephrology, Collegium Medicum, Jagiellonian University in Krakow. CMV infection was demonstrated to occur more frequently and significantly earlier in the patients administered prednisone, cyclosporin A and mycophenolate mofetil, compared to the group treated with standard triple-drug-therapy (prednisone, cyclosporin A, azathioprine) or double-drug-therapy (prednisone, cyclosporin A). Higher serum levels of cyclosporin A did not increase prevalence of the infection but urged its onset. Risk for CMV infection was however higher in the group of patients treated for acute rejection episodes, especially with antilymphocyte preparations. No differences were shown in the immunological matching within HLA-A, -B and -DR antigens between the patients without features of CMV Infection and those treated for its active form. The infection occurred significantly more frequently in the recipients with HLA-A1 antigen than in those with HLA-A9 and -DR7. In patients with delayed transplanted kidney functioning, time of the infection onset and a number of its episodes were similar to the remaining population, however severity of the clinical course positively correlated with the duration of acute tubular necrosis (ATN). CMV infection occurred slightly more frequently in patients requiring transfusions compared to those not administered blood preparations. Among patients with AB blood type, active CMV infection occurred statistically less frequently, whereas in those with other blood types percentage of patients with/without CMV infection were comparable.
authors.affiliation: Katedra i Klinika Nefrologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.
authors.forename: A M
authors.initials: AM
authors.lastname: Szymczakiewicz-Multanowska
authors.forename: M
authors.initials: M
authors.lastname: Kuźniewski
authors.forename: B
authors.initials: B
authors.lastname: Zawilińska
authors.forename: I
authors.initials: I
authors.lastname: Zgórniak-Nowosielska
authors.forename: D
authors.initials: D
authors.lastname: Uracz
authors.forename: E
authors.initials: E
authors.lastname: Ignacak
authors.forename: A
authors.initials: A
authors.lastname: Betkowska-Prokop
authors.forename: W
authors.initials: W
authors.lastname: Sułowicz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000009:adverse effects; D002102:Cadaver; D016572:Cyclosporine / Q000009:adverse effects; D003586:Cytomegalovirus Infections / Q000097:blood / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D011241:Prednisone / Q000009:adverse effects; D015995:Prevalence; D012307:Risk Factors; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D001379:Azathioprine; D011241:Prednisone
vernacular_title: Czynniki wpływajace na wystepowanie i przebieg kliniczny zakazenia wirusem cytomegalii (CMV) u chorych po przeszczepieniu nerki.